Gilead Sciences (GILD) Total Debt (QoQ) (2009 - 2026)
Gilead Sciences (GILD) Total Debt (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,134,969.93 Bn | 92,134,964.97 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,027.45 Bn | 1,022.17 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 559.08 Bn | 537.03 Bn | 15.96 Bn |
| 4 | AbbVie | 394.75 Bn | 385.40 Bn | 10.78 Bn |
| 5 | Merck | 295.12 Bn | 289.47 Bn | 12.09 Bn |
| 6 | Amgen | 186.65 Bn | 174.61 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 159.22 Bn | 151.50 Bn | 5.52 Bn |
| 8 | Pfizer | 146.00 Bn | 133.23 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 113.22 Bn | 102.77 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.02 Bn | 107.33 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.08% |
| Dec 31, 2025 | -0.02% |
| Sep 30, 2025 | -0.02% |
| Jun 30, 2025 | -0.02% |
| Mar 31, 2025 | -6.59% |
| Dec 31, 2024 | 14.89% |
| Sep 30, 2024 | -0.43% |
| Jun 30, 2024 | -7.32% |
| Mar 31, 2024 | 0.83% |
| Dec 31, 2023 | 0.02% |
| Sep 30, 2023 | -1.05% |
| Jun 30, 2023 | 0.03% |
| Mar 31, 2023 | 0.04% |
| Dec 31, 2022 | 0.03% |
| Sep 30, 2022 | -3.79% |
| Jun 30, 2022 | 0.03% |
| Mar 31, 2022 | -1.82% |
| Dec 31, 2021 | -3.58% |
| Sep 30, 2021 | -8.25% |
| Jun 30, 2021 | 0.03% |